Michael Kelly

Chief Scientific Officer

CureDuchenne

Michael  Kelly

Michael Kelly has more than 25 years of experience in drug discovery and development organizations. He is currently the chief scientific officer of CureDuchenne. Prior to that, Mike served as president and U.S. site head of Renovis, Inc., and held positions at Amgen, Wyeth (Pfizer) and Wellcome (GSK) among others. Mike received his Ph.D. from the University of Southampton, and held research positions at the University of Michigan and University of Nottingham; he is an inventor on more than 100 patents and is widely published in peer reviewed journals.